1. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus. Report of Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus. Diabetes in Korea 2007. 1st ed.Seoul: Goldfishery;2007. p. 46.
2. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007; 23:945–52.
Article
3. Chipkin SR. How to select and combine oral agents for patients with type 2 diabetes mellitus. Am J Med. 2005; 118(Suppl 5A):4S–13S.
Article
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287:360–72.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005; 65:385–411.
6. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial. 2010; 23:163–8.
Article
7. KDOQI. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007; 49(2 Suppl 2):S12–154.
8. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34:1431–7.
Article
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.
10. Committee of Clinical Practice Guideline, Korean Diabetes Association. Treatment guideline for diabetes. 4th ed. J Korean Diabetes. 2011; 12(Suppl 1):65–72.
11. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13:7–18.
Article